Mylan's revenue was down due to issues in the North American market, but the company is looking forward to development of new products to balance out losses in the future, including a newly announced Botox biosimilar.
Mylan NV's tie-up with ReVance Therapeutics Inc. for development of a biosimilar version of Botox opens up what the companies see as a large, growing market for neuromodulators.
Mylan announced Feb. 28 that it will be working with Revance to develop and commercialize a biosimilar to Allergan...
Create an account to read this article
Already a subscriber?
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
Novo has lost its lead in the US obesity market but is banking on increasing US patient access and expanding global markets to sustain growth as it continues its fight for Metsera.
Amgen has worked its way through biosimilar and generic competitors for key drugs, with Prolia and Xgeva now challenged, and may have a mega-blockbuster on its hands in obesity.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
